Lavaca Capital LLC trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,011 shares of the company’s stock after selling 235 shares during the period. Lavaca Capital LLC’s holdings in Johnson & Johnson were worth $519,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Virtus ETF Advisers LLC bought a new position in shares of Johnson & Johnson in the second quarter worth approximately $25,000. Krane Funds Advisors LLC bought a new position in shares of Johnson & Johnson during the second quarter worth $26,000. Financial Advantage Inc. bought a new position in shares of Johnson & Johnson during the third quarter worth $28,000. Crewe Advisors LLC boosted its position in shares of Johnson & Johnson by 725.9% during the second quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after acquiring an additional 196 shares during the last quarter. Finally, Eii Capital Management Inc. bought a new position in shares of Johnson & Johnson during the third quarter worth $39,000. 72.22% of the stock is owned by hedge funds and other institutional investors.
Shares of JNJ opened at $131.23 on Thursday. Johnson & Johnson has a twelve month low of $121.00 and a twelve month high of $148.99. The company has a market cap of $347.35 billion, a P/E ratio of 16.04, a P/E/G ratio of 2.23 and a beta of 0.69. The company has a current ratio of 1.26, a quick ratio of 1.00 and a debt-to-equity ratio of 0.46. The company’s fifty day simple moving average is $130.88 and its 200-day simple moving average is $133.92.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.12. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The business had revenue of $20.73 billion for the quarter, compared to the consensus estimate of $20.14 billion. During the same quarter in the prior year, the firm posted $2.05 earnings per share. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. Analysts predict that Johnson & Johnson will post 8.65 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 2.90%. The ex-dividend date of this dividend is Monday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 46.45%.
A number of equities analysts recently weighed in on JNJ shares. Morgan Stanley restated an “equal weight” rating and set a $145.00 target price on shares of Johnson & Johnson in a research report on Tuesday, August 27th. Credit Suisse Group upped their target price on shares of Johnson & Johnson from $158.00 to $163.00 in a research report on Thursday, October 24th. Atlantic Securities upgraded shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research report on Wednesday, October 16th. Raymond James dropped their target price on shares of Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Finally, Goldman Sachs Group set a $169.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Buy” and an average price target of $151.64.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: Bull Market
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.